STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G] Pelthos Therapeutics Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Murchinson Ltd. and Marc Bistricer filed a Schedule 13G reporting beneficial ownership of Pelthos Therapeutics Inc. common stock. They report 280,000 shares, representing 9.1% of the class, with shared voting power and shared dispositive power over 280,000 shares and no sole power over any shares.

The filing identifies the securities as Pelthos Therapeutics Inc. common stock (CUSIP 171126204). The percentage is based on the issuer’s disclosure that 3,090,729 shares were outstanding as of September 30, 2025. Shares are held by one or more funds advised or sub‑advised by Murchinson Ltd., and both the Adviser and Mr. Bistricer state they may be deemed to beneficially own the reported shares, while disclaiming beneficial ownership except to the extent of their pecuniary interest.

Positive
  • None.
Negative
  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Murchinson Ltd.
Signature:/s/ Marc Bistricer
Name/Title:Marc Bistricer, Chief Executive Officer
Date:11/14/2025
Marc Bistricer
Signature:/s/ Marc Bistricer
Name/Title:Marc Bistricer, Individually
Date:11/14/2025

FAQ

Who filed the Schedule 13G for PTHS?

The filing was made by Murchinson Ltd. and Marc Bistricer.

How many Pelthos Therapeutics (PTHS) shares are beneficially owned?

They report beneficial ownership of 280,000 shares of common stock.

What percent of Pelthos (PTHS) does this represent?

The filing reports 9.1% of the class.

Do the reporting persons have voting and dispositive power?

They report shared voting power and shared dispositive power over 280,000 shares, and no sole power.

What share count was used to calculate the 9.1% for PTHS?

The calculation is based on 3,090,729 shares outstanding as of September 30, 2025.

How are the shares held according to the filing?

The shares are held by one or more funds advised or sub‑advised by Murchinson Ltd..

Do the reporting persons disclaim beneficial ownership?

Yes. Each disclaims beneficial ownership except to the extent of their pecuniary interest.
Pelthos Therapeutics

NYSE:PTHS

PTHS Rankings

PTHS Latest News

PTHS Latest SEC Filings

PTHS Stock Data

106.18M
1.11M
64.2%
10.43%
0.18%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
DURHAM